Ebba Biotech welcomes you to listen to our resident expert from the Center for the Advancement of the Integrated Medical and Engineering Sciences (AIMES) at Karolinska Institutet, Sweden - Dr. Susanne Löffler.
During this talk titled "Opto-electronically active Materials for Infection Detection and Control", Dr. Löffler will be presenting AIMES research about using optotracers for infection detection and control.
Read more about Dr. Löffler's work at AIMES here: https://aimes.se/
About Dr. Löffler
As a Group Leader at the Center for the Advancement of Integrated Medical and Engineering Sciences (AIMES) based in Stockholm, Sweden, Dr. Löffler specialises in Organic Bioelectronics for Bacterial Infection. Her background in biomedical sciences and signal processing make her uniquely suited to develop novel and specialised tools for data management, visualisation and analysis for bacterial detection technologies.
With an academic career starting at the University of Lübeck with both an MSc in Molecular Life Sciences and a PhD covering the specialisation in neural recordings and microstimulation, Dr. Löffler now spends her time bringing new exciting scientific applications to the commercial and entrepreneurial space. This being done through her work consulting life science start ups whilst still maintaining her position at AIMES.
Dr. Löffler describes research using optotracers. The optotracers described during the webinar are commercially available under the product family name EbbaBiolight, which are marketed and sold by Ebba Biotech.
Ebba Biotech welcomes you to listen to Dr. Ashraf Zarkan from University of Cambridge presenting his work on antibiofilm therapies for urinary tract infections using EbbaBiolight.
About the speaker: Ashraf Zarkan is a microbiologist with a pharmaceutical background, holding a PhD in Biochemistry from the University of Cambridge. He did his bachelor’s degree in Pharmacy and Pharmaceutical Chemistry followed by an MSc in Microbiology. He has a broad repertoire of training skills that range from experimental research to computational approaches to data analysis. Ash is passionate about tackling the increasing problem with antibiotic resistance, and his research has been focused on developing antibiotic adjuvants. He has a solid experience in bacterial signalling and antibiotic action, side effects, and combinations with adjuvants.
Abstract: Serious bacterial infections represent an unprecedented worldwide threat, due mainly to the emergence of antibiotic-resistant bacteria for which we have limited therapies. Antibiotic resistance is on the rise and has recently been identified as one of the World Health Organization’s global health challenges in the next decade. A key aspect of the antibiotic resistance problem is the ability of bacteria to form biofilms, which provide protection from both antibiotics and the host immune system. Biofilms are implicated in chronic infections such as urinary tract infections (UTIs). UTIs are among the most prevalent bacterial infections, affecting 150 million people per year worldwide, with 75% of infections occurring due to uropathogenic E. coli. Research by Dr Zarkan and his colleagues from the University of Cambridge highlighted the inhibition of an E. coli enzyme as a plausible route to inhibit biofilm formation, thereby reduce pathogenicity and increase antibiotic effectiveness in UTIs. In this webinar, you will learn how a collaboration between the University of Cambridge and Ebba Biotech AB successfully confirmed the antibiofilm properties of a set of novel inhibitors in clinical strains of uropathogenic E. coli. The current focus is in optimising these hits and completing pre-clinical development to be able to move further into clinical trials.
Ebba Biotech welcomes you to listen to Dr. Karen Butina present her research findings using EbbaBiolight-like molecules. This webinar will focus on the use of the Optotracer molecules and technology applied on Staphylococci bacteria. You can read more about Dr. Butina's work here. DISCLAIMER: Dr. Butina describes her work using HS-167 molecules. These are predecessor molecules to what is now commercialised under the product family name EbbaBiolight, which are marketed and sold by Ebba Biotech.
Originally from Slovenia, Dr. Butina received her Bachelor’s degree in Biotechnology in Ljubljana before pursuing her Masters and PhD at KI in Sweden. At KI she was part of the pioneering team (Prof. Richter Dahlfors Group) behind the Optotracer technology within microbiology. Her extensive background in interdisciplinary work has broadened her interests within the medical field and she continuously strives to find out how things work and develop applications to contribute to an equal society.